Trade Inovio Pharmaceuticals, Inc. - INO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0400 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Inovio Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.3609 |
Open* | 0.3536 |
1-Year Change* | -81.39% |
Day's Range* | 0.3536 - 0.3762 |
52 wk Range | 0.32-2.12 |
Average Volume (10 days) | 2.23M |
Average Volume (3 months) | 74.04M |
Market Cap | 114.16M |
P/E Ratio | -100.00K |
Shares Outstanding | 272.99M |
Revenue | 854.03K |
EPS | -0.64 |
Dividend (Yield %) | N/A |
Beta | 1.02 |
Next Earnings Date | Feb 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 30, 2023 | 0.3708 | 0.0096 | 2.66% | 0.3612 | 0.3765 | 0.3530 |
Nov 29, 2023 | 0.3609 | -0.0132 | -3.53% | 0.3741 | 0.3855 | 0.3553 |
Nov 28, 2023 | 0.3807 | -0.0222 | -5.51% | 0.4029 | 0.4029 | 0.3670 |
Nov 27, 2023 | 0.3925 | 0.0023 | 0.59% | 0.3902 | 0.4053 | 0.3875 |
Nov 24, 2023 | 0.3989 | 0.0162 | 4.23% | 0.3827 | 0.3989 | 0.3827 |
Nov 22, 2023 | 0.3889 | -0.0003 | -0.08% | 0.3892 | 0.3947 | 0.3808 |
Nov 21, 2023 | 0.3882 | -0.0093 | -2.34% | 0.3975 | 0.3975 | 0.3813 |
Nov 20, 2023 | 0.3970 | 0.0040 | 1.02% | 0.3930 | 0.4018 | 0.3815 |
Nov 17, 2023 | 0.4086 | 0.0151 | 3.84% | 0.3935 | 0.4098 | 0.3815 |
Nov 16, 2023 | 0.3872 | 0.0122 | 3.25% | 0.3750 | 0.4068 | 0.3649 |
Nov 15, 2023 | 0.3650 | 0.0173 | 4.98% | 0.3477 | 0.3764 | 0.3477 |
Nov 14, 2023 | 0.3529 | 0.0079 | 2.29% | 0.3450 | 0.3626 | 0.3422 |
Nov 13, 2023 | 0.3349 | 0.0051 | 1.55% | 0.3298 | 0.3349 | 0.3293 |
Nov 10, 2023 | 0.3283 | -0.0162 | -4.70% | 0.3445 | 0.3445 | 0.3138 |
Nov 9, 2023 | 0.3359 | -0.0191 | -5.38% | 0.3550 | 0.3550 | 0.3335 |
Nov 8, 2023 | 0.3526 | -0.0139 | -3.79% | 0.3665 | 0.3665 | 0.3421 |
Nov 7, 2023 | 0.3624 | -0.0048 | -1.31% | 0.3672 | 0.3742 | 0.3611 |
Nov 6, 2023 | 0.3750 | -0.0099 | -2.57% | 0.3849 | 0.3858 | 0.3670 |
Nov 3, 2023 | 0.3823 | 0.0153 | 4.17% | 0.3670 | 0.4120 | 0.3664 |
Nov 2, 2023 | 0.3753 | 0.0373 | 11.04% | 0.3380 | 0.3783 | 0.3374 |
Inovio Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 28, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 Inovio Pharmaceuticals Inc Earnings Release Q4 2023 Inovio Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 10.2623 | 1.77476 | 7.41122 | 4.11193 | 30.4819 |
Revenue | 10.2623 | 1.77476 | 7.41122 | 4.11193 | 30.4819 |
Total Operating Expense | 277.836 | 302.993 | 126.787 | 115.22 | 124.573 |
Selling/General/Admin. Expenses, Total | 90.1853 | 53.7523 | 37.2478 | 27.2032 | 29.3152 |
Research & Development | 187.65 | 249.24 | 94.2454 | 88.0173 | 95.2579 |
Unusual Expense (Income) | 0 | 0 | -4.70606 | 0 | 0 |
Operating Income | -267.574 | -301.218 | -119.376 | -111.109 | -94.0911 |
Interest Income (Expense), Net Non-Operating | -6.21775 | -2.34978 | -42.8094 | -10.1968 | -0.70688 |
Net Income Before Taxes | -277.653 | -303.224 | -162.89 | -120.809 | -94.798 |
Net Income After Taxes | -277.653 | -303.224 | -162.89 | -120.552 | -96.9678 |
Minority Interest | 0 | 0 | 1.06376 | 1.19256 | |
Net Income Before Extra. Items | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Net Income | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Income Available to Common Excl. Extra. Items | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Income Available to Common Incl. Extra. Items | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Diluted Net Income | -279.818 | -303.659 | -166.411 | -119.359 | -96.9678 |
Diluted Weighted Average Shares | 238.622 | 208.83 | 155.127 | 98.718 | 92.54 |
Diluted EPS Excluding Extraordinary Items | -1.17264 | -1.4541 | -1.07274 | -1.20909 | -1.04785 |
Diluted Normalized EPS | -1.17264 | -1.4541 | -1.10308 | -1.20909 | -1.04785 |
Total Extraordinary Items | |||||
Other, Net | -3.86158 | 0.34337 | -0.7049 | 0.4962 | |
Equity In Affiliates | -2.16521 | -0.43439 | -4.58461 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0.22597 | 0.11494 | 0.12467 | 9.15413 | 0.7844 |
Revenue | 0.22597 | 0.11494 | 0.12467 | 9.15413 | 0.7844 |
Total Operating Expense | 37.2671 | 44.0671 | 56.0708 | 44.9112 | 104.922 |
Selling/General/Admin. Expenses, Total | 13.5231 | 13.8906 | 13.9509 | 11.824 | 48.4568 |
Research & Development | 21.744 | 30.1765 | 42.1199 | 33.0871 | 56.4649 |
Operating Income | -37.0411 | -43.9522 | -55.9462 | -35.757 | -104.137 |
Interest Income (Expense), Net Non-Operating | 2.93443 | 5.72854 | 4.2473 | -1.08608 | -4.35694 |
Other, Net | -1.42787 | -2.42568 | -2.76429 | -0.94078 | -0.00305 |
Net Income Before Taxes | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Net Income After Taxes | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Minority Interest | 0 | ||||
Equity In Affiliates | 0 | 0 | 0 | 0 | 0 |
Net Income Before Extra. Items | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Net Income | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Income Available to Common Excl. Extra. Items | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Income Available to Common Incl. Extra. Items | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Diluted Net Income | -35.5345 | -40.6493 | -54.4631 | -37.7839 | -108.497 |
Diluted Weighted Average Shares | 264.354 | 258.438 | 250.585 | 249.351 | 235.278 |
Diluted EPS Excluding Extraordinary Items | -0.13442 | -0.15729 | -0.21734 | -0.15153 | -0.46114 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.12685 | -0.15729 | -0.21734 | -0.15153 | -0.46114 |
Unusual Expense (Income) | 2 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 315.243 | 448.445 | 471.171 | 94.201 | 87.8148 |
Cash and Short Term Investments | 252.999 | 401.315 | 411.643 | 89.5341 | 81.2325 |
Cash & Equivalents | 46.3294 | 71.1438 | 250.728 | 22.1961 | 23.6936 |
Short Term Investments | 206.669 | 330.171 | 160.915 | 67.338 | 57.5388 |
Total Receivables, Net | 11.7382 | 8.03204 | 19.0637 | 2.03212 | 4.05494 |
Accounts Receivable - Trade, Net | 1.70173 | 5.46685 | 18.56 | 0.70007 | 3.31636 |
Prepaid Expenses | 50.5057 | 39.0982 | 40.4639 | 2.63474 | 2.5274 |
Total Assets | 348.533 | 495.941 | 539.772 | 143.952 | 131.113 |
Property/Plant/Equipment, Total - Net | 17.9562 | 29.0242 | 24.0894 | 26.556 | 15.949 |
Property/Plant/Equipment, Total - Gross | 39.5196 | 47.9686 | 40.083 | 39.7225 | 25.9489 |
Accumulated Depreciation, Total | -21.5634 | -18.9444 | -15.9936 | -13.1665 | -9.99992 |
Goodwill, Net | 10.5134 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
Intangibles, Net | 2.12986 | 2.62636 | 3.14677 | 3.69385 | 4.76015 |
Long Term Investments | 2.00714 | 3.9068 | 4.89475 | 6.31536 | 9.40591 |
Other Long Term Assets, Total | 0.68404 | 1.42579 | 25.9575 | 2.67202 | 2.67 |
Total Current Liabilities | 96.8681 | 65.7416 | 41.706 | 31.9893 | 35.2998 |
Accounts Payable | 19.8625 | 24.2137 | 0.82552 | 6.91908 | 10.0438 |
Payable/Accrued | 45.2204 | 0.54803 | 0.64297 | 0.72973 | 4.60189 |
Accrued Expenses | 29.2224 | 36.3611 | 32.658 | 17.4428 | 15.1386 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.5627 | 4.61885 | 7.57944 | 6.89777 | 5.51547 |
Total Liabilities | 126.171 | 96.2721 | 78.6317 | 140.516 | 44.1771 |
Total Long Term Debt | 16.6148 | 14.9597 | 18.6558 | 77.0229 | 0 |
Deferred Income Tax | 0.03205 | 0.03205 | 0.03205 | 0.03205 | 0.02477 |
Minority Interest | 0 | 1.96976 | 0.09627 | ||
Other Liabilities, Total | 12.6556 | 15.5387 | 18.2379 | 29.5025 | 8.75633 |
Total Equity | 222.363 | 399.669 | 461.141 | 3.4351 | 86.9361 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.25309 | 0.21738 | 0.18685 | 0.10136 | 0.09723 |
Additional Paid-In Capital | 1710.66 | 1609.59 | 1367.41 | 742.647 | 707.794 |
Retained Earnings (Accumulated Deficit) | -1487.85 | -1209.86 | -906.197 | -739.786 | -620.426 |
Other Equity, Total | -0.69874 | -0.28224 | -0.25615 | 0.47261 | -0.52887 |
Total Liabilities & Shareholders’ Equity | 348.533 | 495.941 | 539.772 | 143.952 | 131.113 |
Total Common Shares Outstanding | 253.091 | 217.383 | 186.851 | 101.361 | 97.2258 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00001 | 0.00002 | 0.00002 |
Long Term Debt | 16.6148 | 14.9597 | 18.6558 | 77.0229 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 174.767 | 203.284 | 233.896 | 315.243 | 350.208 |
Cash and Short Term Investments | 167.473 | 194.925 | 223.751 | 252.999 | 281.883 |
Cash & Equivalents | 18.8046 | 52.7125 | 28.2381 | 46.3294 | 21.9882 |
Short Term Investments | 148.669 | 142.213 | 195.513 | 206.669 | 259.895 |
Total Receivables, Net | 2.14393 | 5.11623 | 5.03511 | 11.7382 | 10.0807 |
Accounts Receivable - Trade, Net | 0 | 0.00595 | 0.0733 | 1.70173 | 2.44287 |
Prepaid Expenses | 5.1498 | 3.24281 | 5.11017 | 50.5057 | 58.2442 |
Total Assets | 193.097 | 233.038 | 266.583 | 348.533 | 391.968 |
Property/Plant/Equipment, Total - Net | 14.7298 | 15.7927 | 16.8489 | 17.9562 | 26.1652 |
Goodwill, Net | 0 | 10.5134 | 10.5134 | 10.5134 | 10.5134 |
Intangibles, Net | 0 | 0 | 2.04778 | 2.12986 | 2.24944 |
Long Term Investments | 2.9949 | 2.78053 | 2.62378 | 2.00714 | 2.12999 |
Other Long Term Assets, Total | 0.60532 | 0.66689 | 0.65252 | 0.68404 | 0.70199 |
Total Current Liabilities | 43.711 | 51.9323 | 55.1511 | 96.8681 | 94.9147 |
Payable/Accrued | 0.71172 | 1.68638 | 1.41727 | 80.9073 | 75.7816 |
Accrued Expenses | 19.4909 | 21.1189 | 21.9336 | 13.3981 | 16.3067 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 3.82808 | 3.74862 | 4.211 | 2.5627 | 2.82645 |
Total Liabilities | 54.9375 | 63.6664 | 67.369 | 126.171 | 125.271 |
Total Long Term Debt | 0 | 0 | 0 | 16.6148 | 16.3013 |
Long Term Debt | 0 | 0 | 0 | 16.6148 | 16.3013 |
Deferred Income Tax | 0.03205 | 0.03205 | 0.03205 | 0.03205 | 0.03205 |
Other Liabilities, Total | 11.1944 | 11.702 | 12.1859 | 12.6556 | 14.0227 |
Total Equity | 138.16 | 169.372 | 199.214 | 222.363 | 266.697 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.26973 | 0.26807 | 0.26274 | 0.25309 | 0.24948 |
Additional Paid-In Capital | 1736.6 | 1733.83 | 1728.03 | 1710.66 | 1700.72 |
Retained Earnings (Accumulated Deficit) | -1597.96 | -1564.03 | -1528.5 | -1487.85 | -1433.38 |
Other Equity, Total | -0.75107 | -0.69126 | -0.5828 | -0.69874 | -0.88521 |
Total Liabilities & Shareholders’ Equity | 193.097 | 233.038 | 266.583 | 348.533 | 391.968 |
Total Common Shares Outstanding | 269.731 | 268.073 | 262.739 | 253.091 | 249.485 |
Total Preferred Shares Outstanding | 0.00001 | 0.00001 | 0.00001 | 0.00001 | 0.00001 |
Accounts Payable | 3.19205 | 8.67007 | 11.1944 | ||
Current Port. of LT Debt/Capital Leases | 16.4883 | 16.7083 | 16.3948 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -279.818 | -303.659 | -167.475 | -120.552 | -96.9678 |
Cash From Operating Activities | -216.215 | -215.709 | -177.979 | -97.8501 | -73.5502 |
Cash From Operating Activities | 3.65671 | 3.0401 | 3.039 | 3.59839 | 3.74718 |
Amortization | 0.49649 | 0.52042 | 0.54708 | 1.06629 | 1.24958 |
Deferred Taxes | 0 | 0 | 0.0054 | 0 | |
Non-Cash Items | 39.6153 | 34.0382 | 56.9816 | 21.5747 | 13.3131 |
Changes in Working Capital | 19.8342 | 50.3515 | -71.0718 | -3.54312 | 5.10778 |
Cash From Investing Activities | 109.586 | -175.344 | -58.7957 | -9.045 | 42.4199 |
Capital Expenditures | -0.96915 | -1.23101 | -1.52067 | -0.98793 | -2.08502 |
Other Investing Cash Flow Items, Total | 110.555 | -174.113 | -57.2751 | -8.05707 | 44.5049 |
Cash From Financing Activities | 81.8407 | 211.499 | 465.28 | 105.398 | 31.0373 |
Financing Cash Flow Items | 0 | 0 | 2.37997 | -0.35463 | 0 |
Issuance (Retirement) of Stock, Net | 81.8407 | 211.499 | 462.728 | 8.3086 | 31.0373 |
Foreign Exchange Effects | -0.02556 | -0.03013 | 0.02721 | ||
Net Change in Cash | -24.8144 | -179.584 | 228.532 | -1.49754 | -0.09295 |
Cash Interest Paid | 1.06698 | 1.0778 | 4.62476 | 2.71759 | |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0.17162 | 97.4436 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -40.6493 | -279.818 | -225.355 | -187.571 | -79.0737 |
Cash From Operating Activities | -36.6645 | -216.215 | -179.875 | -112.41 | -61.8821 |
Cash From Operating Activities | 0.70738 | 3.65671 | 2.77667 | 1.86996 | 0.92938 |
Amortization | 0.08208 | 0.49649 | 0.37691 | 0.25733 | 0.12677 |
Non-Cash Items | 1.7177 | 39.6153 | 35.4049 | 29.4844 | 15.7913 |
Cash Interest Paid | 0.53349 | 1.06698 | 1.06698 | 0.53349 | 0.53349 |
Changes in Working Capital | 1.47767 | 19.8342 | 6.92106 | 43.5492 | 0.3442 |
Cash From Investing Activities | 18.9999 | 109.586 | 55.585 | 11.0283 | 21.3323 |
Capital Expenditures | -0.29698 | -0.96915 | -0.80404 | -0.71721 | 0 |
Other Investing Cash Flow Items, Total | 19.2969 | 110.555 | 56.3891 | 11.7456 | 21.3323 |
Cash From Financing Activities | -0.4247 | 81.8407 | 75.1727 | 71.3612 | 28.422 |
Financing Cash Flow Items | 0 | ||||
Issuance (Retirement) of Stock, Net | -0.4247 | 81.8407 | 75.1727 | 71.3612 | 28.422 |
Foreign Exchange Effects | -0.00192 | -0.02556 | -0.0379 | -0.02134 | -0.00656 |
Net Change in Cash | -18.0912 | -24.8144 | -49.1555 | -30.0419 | -12.1343 |
Issuance (Retirement) of Debt, Net | 0 | ||||
Deferred Taxes |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.4859 | 20067883 | 1833565 | 2023-06-30 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 2.8358 | 7602133 | 983289 | 2023-06-30 | MED |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.2258 | 5966835 | -13954601 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 2.0279 | 5436281 | 2795981 | 2023-06-30 | HIGH |
Millennium Management LLC | Hedge Fund | 1.9921 | 5340253 | 5340253 | 2023-06-30 | HIGH |
Jane Street Capital, L.L.C. | Research Firm | 1.1922 | 3196081 | 2261961 | 2023-06-30 | HIGH |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.1191 | 3000096 | -64550 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0673 | 2861243 | -2315538 | 2023-06-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.8909 | 2388228 | 2367628 | 2023-06-30 | HIGH |
Kim (Jong Joseph Ph.D.) | Individual Investor | 0.8751 | 2346000 | 0 | 2023-03-17 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.801 | 2147319 | 969218 | 2023-06-30 | MED |
GMT Capital Corp. | Hedge Fund | 0.5646 | 1513500 | 1513500 | 2023-06-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.4704 | 1260963 | -501449 | 2023-06-30 | LOW |
Qube Research & Technologies Ltd | Hedge Fund | 0.3522 | 944190 | 549920 | 2023-06-30 | HIGH |
Weiner (David B) | Individual Investor | 0.3466 | 929124 | 19000 | 2023-05-16 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3273 | 877447 | -27034933 | 2023-06-30 | LOW |
Susquehanna International Group, LLP | Investment Advisor | 0.2825 | 757413 | -115730 | 2023-06-30 | MED |
BofA Global Research (US) | Research Firm | 0.2499 | 669960 | -2850667 | 2023-06-30 | LOW |
Y-Intercept (Hong Kong) Ltd | Investment Advisor | 0.2364 | 633613 | 633613 | 2023-06-30 | HIGH |
Green Alpha Advisors, LLC | Investment Advisor | 0.2126 | 570049 | 387752 | 2023-09-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Inovio Pharmaceuticals Company profile
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system''s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.Industry: | Biotechnology & Medical Research (NEC) |
6769 Mesa Ridge Rd.
SAN DIEGO
CALIFORNIA 92121
US
Income Statement
- Annual
- Quarterly
News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com